Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bevacizumab; Cediranib; Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Clinical diagnosis of colon or rectal cancer,

• Received prior systemic therapy for cancer,

• Cancer must have progressed during or after first treatment

Exclusion Criteria:

• Prior treatment with a VEGF inhibitor,

• Poorly controlled hypertension